Drug Search Results
More Filters [+]

PF-07329640

Alternative Names: PF-07329640, PF 07329640, PF07329640
Latest Update: 2024-08-19
Latest Update Note: Clinical Trial Update

Product Description

αLTβR (PF-07329640): Activating the Lymphotoxin-β Receptor, a Highly Differentiated Approach to Immunotherapy. (Sourced from: https://s28.q4cdn.com/781576035/files/doc_downloads/2024/02/29/Pfizer-Oncology-Innovation-Day-Presentation_FINAL.pdf)

Mechanisms of Action: LTBR Inhibitor

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for PF-07329640

Countries in Clinic: Puerto Rico, United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Colorectal Cancer|Melanoma|Non-Small-Cell Lung Cancer|Transitional Cell Carcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

LTbR

P1

Active, not recruiting

Colorectal Cancer|Melanoma|Non-Small-Cell Lung Cancer|Transitional Cell Carcinoma

2024-08-16

Recent News Events

Date

Type

Title